Why It Matters
Cencora faces a critical juncture where pharmacy distribution margins face pressure from multiple directions. PBM reform legislation threatens to reshape reimbursement dynamics, while executive branch drug pricing initiatives and Inflation Reduction Act implementation compress pricing throughout the supply chain. The company’s lobbying strategy targets legislative solutions to shore up its pharmacy customer base through access bills while protecting tax benefits and positioning itself as essential to emerging supply chain resilience programs.
By the Numbers
Cencora Inc. spent $680,000 on in-house lobbying in the third quarter of 2025, continuing nearly two decades of consistent advocacy. The company has filed 74 in-house disclosures since 2005 and spent over $32.9 million total on lobbying.
Cencora’s three-person team is led by Vivienne Elizabeth Stafford Mitchell, who has represented the company for over 14 years across 42 disclosures totaling $22.45 million. Darrell Rogers joined in January 2024, while Shelly Mui-Lipnik arrived in April 2023 with prior experience at Novartis and the Biotechnology Innovation Organization.
The company retained no external firms this quarter, though historically it has worked with 37 external firms, including Horizon Government Affairs ($2.3M spent 2011-2025).
The Agenda
Cencora is lobbying on four major areas. On taxes, the company is pushing for preservation of the Last-In, First-Out (LIFO) accounting method and favorable Global Intangible Low-taxed Income treatment. Healthcare efforts focus on drug shortage mitigation, supply chain resilience initiatives including Strategic National Stockpile reauthorization, and Inflation Reduction Act implementation.
Pharmacy-focused efforts include supporting the Ensuring Seniors Access to Critical Medications Act (H.R. 3164) and the Equitable Community Access to Pharmacist Services Act (S.2426) to shore up independent pharmacies facing PBM pressure.
On Medicare and Medicaid, Cencora is engaged on reimbursement policies, Part B drug pricing, and the Medicare drug negotiation program.
Broader Context
Congress is intensifying pressure on pharmacy benefit managers, with The PBM Reform Act of 2025 (H.R. 4317) advancing to ban spread pricing and clawbacks. This matters for Cencora because independent pharmacies—a core customer base—face accelerating closures due to PBM reimbursement pressures.
The Trump administration is pursuing aggressive drug pricing through executive orders tying U.S. prices to international benchmarks. The Inflation Reduction Act’s Medicare drug price negotiation program is expanding from theory to implementation.
On supply chain resilience, an Executive Order established a Strategic Active Pharmaceutical Ingredients Reserve, while bipartisan congressional legislation seeks to strengthen medical supply chains.
Between The Lines
Congressional committees are holding hearings on allegedly anti-competitive PBM practices, with Rep. Pat Ryan (D-NY-18) demanding PBM reform be included in government funding legislation. Senators Rand Paul and Maggie Hassan have reintroduced legislation to streamline generic drug approvals, signaling bipartisan commitment to addressing pharmaceutical supply chain vulnerabilities.
Competitive Landscape
Cencora operates within a heavily lobbied pharmaceutical sector. Organizations like PhRMA are actively engaged on overlapping issues, particularly drug pricing and Medicare policy.
Cencora’s lobbying on pharmacy access positions it alongside independent pharmacy advocates seeking to counter PBM consolidation—a defensive posture as pharmacy closures accelerated and contracted Cencora’s customer base. On supply chain resilience, Cencora’s advocacy aligns with broader bipartisan efforts.
The Bottom Line
Cencora spent $680,000 lobbying amid significant pharmaceutical policy upheaval. The company is navigating concurrent pressures from PBM reform, executive drug pricing initiatives, and Inflation Reduction Act implementation. With drug pricing negotiations expanding and new federal supply chain initiatives underway, Cencora views this period as critical to protecting margins and customer viability in a rapidly shifting market.